Filing Details
- Accession Number:
- 0000950170-24-002134
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-04 18:35:20
- Reporting Period:
- 2024-01-02
- Accepted Time:
- 2024-01-04 18:35:20
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1178879 | Amicus Therapeutics Inc. | FOLD | Pharmaceutical Preparations (2834) | 200422823 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1400971 | L Bradley Campbell | 47 Hulfish Street Princeton NJ 08542 | President And Ceo | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-01-02 | 153,810 | $0.00 | 963,257 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2024-01-02 | 15,452 | $14.24 | 947,805 | No | 4 | F | Direct | |
| Common Stock | Acquisiton | 2024-01-02 | 7,500 | $8.61 | 955,305 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-01-02 | 7,500 | $14.24 | 947,805 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-01-02 | 8,333 | $12.28 | 956,138 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-01-02 | 8,333 | $14.23 | 947,805 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-01-03 | 41,474 | $13.53 | 906,331 | No | 4 | F | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | F | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | F | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (right to buy) | Acquisiton | 2024-01-02 | 265,517 | $0.00 | 265,517 | $14.24 |
| Common Stock | Stock Options (right to buy) | Disposition | 2024-01-02 | 7,500 | $0.00 | 7,500 | $8.61 |
| Common Stock | Stock Options (right to buy) | Disposition | 2024-01-02 | 8,333 | $0.00 | 8,333 | $12.28 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 265,517 | 2034-01-02 | No | 4 | A | Direct | |
| 82,500 | 2025-01-02 | No | 4 | M | Direct | |
| 91,667 | 2025-06-01 | No | 4 | M | Direct |
Footnotes
- Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in four equal annual installments beginning on January 2, 2025 and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock.
- This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.96 to $14.49 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.95 to $14.52 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter.
- All of the options were fully vested and exercisable as of the transaction date.
Billionaire Hedge Funds
